The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Activation of the interferon‐α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
Abstract
Objective: Gene‐expression studies have demonstrated increased expression of interferon (IFN)–inducible genes (IFIGs) in peripheral blood mononuclear cells (PBMCs) of many patients with systemic lupus erythematosus (SLE), with a predominant effect of type I IFN. This study examined the hypothesis that increased disease severity and activity, as well as distinct autoantibody specificities, characterize SLE patients with activation of the type I IFN pathway. Methods: Freshly isolated PBMCs from 77 SLE patients, 22 disease controls, and 28 healthy donors were subjected to real‐time polymerase chain reaction for 3 IFIGs that are preferentially induced by IFNα, and the data were used to derive IFNα scores for all individuals. Expression of IFIGs was significantly higher in SLE patients compared with disease controls or healthy donors. SLE patients with high and low IFNα scores were compared for clinical manifestations of disease, disease severity, disease activity, serologic features, and potential confounders, by bivariate and multivariate analyses. Results: SLE patients with a high IFNα score had a significantly higher prevalence of renal disease, a greater number of American College of Rheumatology criteria for SLE, and a higher Systemic Lupus International Collaborating Clinics damage index (SDI) score than did SLE patients with low IFNα scores. Patients with high scores showed increased disease activity, as measured by lower C3 levels, hemoglobin levels, absolute lymphocyte counts, and albumin levels, and a higher anti–double‐stranded DNA (dsDNA) titer, erythrocyte sedimentation rate, and SLE Disease Activity Index 2000 score. The presence of antibodies specific for Ro, U1 RNP, Sm, and dsDNA, but not phospholipids, was significantly associated with a high IFNα score. Logistic regression analysis confirmed that renal disease, higher SDI scores, low complement levels, and presence of anti–RNA binding protein (RBP) autoantibodies were associated with a high IFNα score. Conclusion: Activation of the IFNα pathway defines a subgroup of SLE patients whose condition is characterized by increased disease severity, including renal disease, increased disease activity, reflected in complement activation, and autoreactivity to RBP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX
(2007) · Systemic Lupus Erythematosus · doi:10.1016/b978-0-323-04434-9.50060-9 · Cited by 2,928
Gladman, D., Ginzler, E., Goldsmith, C., Fortin, P., Liang, M., Sanchez‐Guerrero, J., Urowitz, M., Bacon, P., Bombardieri, S., Hanly, J., et al. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390303 · Cited by 2,582
Baechler, E. C., Batliwalla, F. M., Karypis, G., Gaffney, P. M., Ortmann, W. A., Espe, K. J., Shark, K. B., Grande, W. J., Hughes, K. M., Kapur, V., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337679100 · Cited by 2,240
Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood
Bennett, L., Palucka, A. K., Arce, E., Cantrell, V., Borvak, J., Banchereau, J., & Pascual, V. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021553 · Cited by 1,958
Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J., & Marshak-Rothstein, A. (2002) · Nature · doi:10.1038/416603a · Cited by 1,900
Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Roman, M. J., Shanker, B.-A., Davis, A., Lockshin, M. D., Sammaritano, L., Simantov, R., Crow, M. K., Schwartz, J. E., Paget, S. A., Devereux, R. B., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035471 · Cited by 1,427
Self-citation
Cited by
Vitamin D and the immune system
Aranow, C. (2011) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31821b8755 · Cited by 1,436
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Self-citationTian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372
Self-citationToll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116
Christensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A., & Shlomchik, M. J. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.013 · Cited by 1,090
Immunomodulatory functions of type I interferons
González-Navajas, J. M., Lee, J., David, M., & Raz, E. (2012) · Nature Reviews Immunology · doi:10.1038/nri3133 · Cited by 1,011
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
Banchereau, R., Hong, S., Cantarel, B., Baldwin, N., Baisch, J., Edens, M., Cepika, A.-M., Acs, P., Turner, J., Anguiano, E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.008 · Cited by 731
Denny, M. F., Yalavarthi, S., Zhao, W., Thacker, S. G., Anderson, M., Sandy, A. R., McCune, W. J., & Kaplan, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902199 · Cited by 701
TLR7 escapes X chromosome inactivation in immune cells
Souyris, M., Cenac, C., Azar, P., Daviaud, D., Canivet, A., Grunenwald, S., Pienkowski, C., Chaumeil, J., Mejía, J. E., & Guéry, J.-C. (2018) · Science Immunology · doi:10.1126/sciimmunol.aap8855 · Cited by 641
Type I Interferon in the Pathogenesis of Lupus
Crow, M. K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1002795 · Cited by 561
Self-citationVollmer, J., Tluk, S., Schmitz, C., Hamm, S., Jurk, M., Forsbach, A., Akira, S., Kelly, K. M., Reeves, W. H., Bauer, S., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051696 · Cited by 513
Khamashta, M., Merrill, J. T., Werth, V. P., Furie, R., Kalunian, K., Illei, G. G., Drappa, J., Wang, L., & Greth, W. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208562 · Cited by 503
Feng, X., Wu, H., Grossman, J. M., Hanvivadhanakul, P., FitzGerald, J. D., Park, G. S., Dong, X., Chen, W., Kim, M. H., Weng, H. H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22044 · Cited by 487
Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling
Gough, D. J., Messina, N. L., Clarke, C. J. P., Johnstone, R. W., & Levy, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.011 · Cited by 470
The BAFF/APRIL system in SLE pathogenesis
Vincent, F. B., Morand, E. F., Schneider, P., & Mackay, F. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.33 · Cited by 448
Rice, G. I., Forte, G. M. A., Szynkiewicz, M., Chase, D. S., Aeby, A., Abdel-Hamid, M. S., Ackroyd, S., Allcock, R., Bailey, K. M., Balottin, U., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70258-8 · Cited by 443
Mapping systemic lupus erythematosus heterogeneity at the single-cell level
Nehar-Belaid, D., Hong, S., Marches, R., Chen, G., Bolisetty, M., Baisch, J., Walters, L., Punaro, M., Rossi, R. J., Chung, C.-H., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0743-0 · Cited by 432
Chiche, L., Jourde‐Chiche, N., Whalen, E., Presnell, S., Gersuk, V., Dang, K., Anguiano, E., Quinn, C., Burtey, S., Berland, Y., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38628 · Cited by 420
High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus
Niewold, T. B., Hua, J., Lehman, T. J. A., Harley, J. B., & Crow, M. K. (2007) · Genes & Immunity · doi:10.1038/sj.gene.6364408 · Cited by 416
Self-citationLai, Z.-W., Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Tily, H., Francis, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30485-9 · Cited by 412
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C. (2006) · Lupus · doi:10.1177/0961203306071872 · Cited by 411
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets
Crow, M. K. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223741 · Cited by 398
Self-citationInduction of autoimmunity by pristane and other naturally occurring hydrocarbons
Reeves, W. H., Lee, P. Y., Weinstein, J. S., Satoh, M., & Lu, L. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.06.003 · Cited by 392
Rheumatic diseases: the effects of inflammation on bone
Walsh, N. C., Crotti, T. N., Goldring, S. R., & Gravallese, E. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00338.x · Cited by 380
Interferon pathway in SLE: one key to unlocking the mystery of the disease
Rönnblom, L., & Leonard, D. (2019) · Lupus Science & Medicine · doi:10.1136/lupus-2018-000270 · Cited by 362
Dai, Y., Huang, Y.-S., Tang, M., Lv, T.-Y., Hu, C.-X., Tan, Y.-H., Xu, Z.-M., & Yin, Y.-B. (2007) · Lupus · doi:10.1177/0961203307084158 · Cited by 356
Absher, D. M., Li, X., Waite, L. L., Gibson, A., Roberts, K., Edberg, J., Chatham, W. W., & Kimberly, R. P. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003678 · Cited by 351
Toll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity
Krieg, A. M., & Vollmer, J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00572.x · Cited by 350
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus
Ostendorf, L., Burns, M., Durek, P., Heinz, G. A., Heinrich, F., Garantziotis, P., Enghard, P., Richter, U., Biesen, R., Schneider, U., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2023325 · Cited by 329
Choi, J., Ho, J. H., Pasoto, S. G., Bunin, V., Kim, S. T., Carrasco, S., Borba, E. F., Gonçalves, C. R., Costa, P. R., Kallas, E. G., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39020 · Cited by 326
Hua, J., Kirou, K., Lee, C., & Crow, M. K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21890 · Cited by 317
Self-citationvan der Pouw Kraan, T. C. T. M., Wijbrandts, C. A., van Baarsen, L. G. M., Voskuyl, A. E., Rustenburg, F., Baggen, J. M., Ibrahim, S. M., Fero, M., Dijkmans, B. A. C., Tak, P. P., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.063412 · Cited by 313
Baechler, E. C., Bauer, J. W., Slattery, C. A., Ortmann, W. A., Espe, K. J., Novitzke, J., Ytterberg, S. R., Gregersen, P. K., Behrens, T. W., & Reed, A. M. (2007) · Molecular Medicine · doi:10.2119/2006-00085.baechler · Cited by 311
Altered B cell signalling in autoimmunity
Rawlings, D. J., Metzler, G., Wray-Dutra, M., & Jackson, S. W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.24 · Cited by 308
Type I interferon in the pathogenesis of systemic lupus erythematosus
Postal, M., Vivaldo, J. F., Fernandez-Ruiz, R., Paredes, J. L., Appenzeller, S., & Niewold, T. B. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.10.014 · Cited by 306
New insights into the role of antinuclear antibodies in systemic lupus erythematosus
Pisetsky, D. S., & Lipsky, P. E. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0480-7 · Cited by 303
Weckerle, C. E., & Niewold, T. B. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-009-8192-4 · Cited by 300
Bauer, J. W., Petri, M., Batliwalla, F. M., Koeuth, T., Wilson, J., Slattery, C., Panoskaltsis‐Mortari, A., Gregersen, P. K., Behrens, T. W., & Baechler, E. C. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24803 · Cited by 297
Type I Interferons in Autoimmune Disease
Crow, M. K., Olferiev, M., & Kirou, K. A. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043952 · Cited by 291
Self-citationYao, Y., Richman, L., Higgs, B. W., Morehouse, C. A., de los Reyes, M., Brohawn, P., Zhang, J., White, B., Coyle, A. J., Kiener, P. A., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24557 · Cited by 284
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Cancro, M. P., D’Cruz, D. P., & Khamashta, M. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38010 · Cited by 283
Niewold, T. B., Kelly, J. A., Flesch, M. H., Espinoza, L. R., Harley, J. B., & Crow, M. K. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23613 · Cited by 269
Self-citationType I interferons: crucial participants in disease amplification in autoimmunity
Hall, J. C., & Rosen, A. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.237 · Cited by 265
Role of the NLRP3 inflammasome in autoimmune diseases
Li, Z., Guo, J., & Bi, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110542 · Cited by 261
Tan, F. K., Zhou, X., Mayes, M. D., Gourh, P., Guo, X., Marcum, C., Jin, L., & Arnett, F. C. (2006) · Rheumatology · doi:10.1093/rheumatology/kei244 · Cited by 260
Weckerle, C. E., Franek, B. S., Kelly, J. A., Kumabe, M., Mikolaitis, R. A., Green, S. L., Utset, T. O., Jolly, M., James, J. A., Harley, J. B., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30187 · Cited by 259
Fernandez, D. R., Telarico, T., Bonilla, E., Li, Q., Banerjee, S., Middleton, F. A., Phillips, P. E., Crow, M. K., Oess, S., Muller-Esterl, W., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803600 · Cited by 257
Self-citationInterferons and Their Stimulated Genes in the Tumor Microenvironment
Cheon, H., Borden, E. C., & Stark, G. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.002 · Cited by 255
The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression
Hung, T., Pratt, G. A., Sundararaman, B., Townsend, M. J., Chaivorapol, C., Bhangale, T., Graham, R. R., Ortmann, W., Criswell, L. A., Yeo, G. W., et al. (2015) · Science · doi:10.1126/science.aac7442 · Cited by 254
Ritterhouse, L. L., Crowe, S. R., Niewold, T. B., Kamen, D. L., Macwana, S. R., Roberts, V. C., Dedeke, A. B., Harley, J. B., Scofield, R. H., Guthridge, J. M., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.148494 · Cited by 229
Mavragani, C. P., Nezos, A., Sagalovskiy, I., Seshan, S., Kirou, K. A., & Crow, M. K. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.10.004 · Cited by 85
Self-citationMartínez, B. A., Shrotri, S., Kingsmore, K. M., Bachali, P., Grammer, A. C., & Lipsky, P. E. (2022) · Science Advances · doi:10.1126/sciadv.abn4776 · Cited by 56
“Together, this suggests that IFN is not a dominant factor of nonlesional disease in either CLE or PSO and may instead reflect the concurrent exposure to ultraviolet (UV) light or the presence of specific autoantibodies, both of which are associated with up-regulation of the IGS ( 45 – 47 ).”
Metadata
- Authors
- Kirou, K. A., Lee, C., George, S., Louca, K., Peterson, M. G. E., & Crow, M. K.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2005-05
- Volume
- 52
- Issue
- 5
- Pages
- 1491-1503
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1965672602
- Cited by
- 701
- References
- 49
- FWCI
- 18.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.